ResMed trial fails

Wednesday, May 13, 2015

SAN DIEGO – ResMed announced today that a phase III trial designed to assess whether treating moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation (ASV) therapy could reduce mortality and morbidity in patients with chronic heart failure has missed the mark. A preliminary analysis of the data identified a statistically significant 2.5% increased risk of cardiovascular mortality for those patients in the trial who received ASV therapy per year compared to those in the control group. In the study, the cardiovascular mortality rate in the ASV group was 10% per year compared to 7.5% per year in the control group.